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1. Introduction
  Atenolol, approved for use in the United States in 1981, is a 
cardio selective beta-adrenergic receptor blocker in that it 
has potent activity against beta 1 adrenergic receptors which 
are found in cardiac muscle, but has little or no activity 
against beta 2 adrenergic receptors found on bronchial and 
vascular smooth muscle and is widely used worldwide in 
the treatment of hypertension and angina. It is also used 
to reduce the risk of cardiovascular mortalities in patients 
with coronary artery diseases. The chemical works by 
slowing down the heart and reducing its workload. Unlike 
propranolol, atenolol does not pass through the blood-
brain barrier thus avoiding various central nervous system 
side effects (http://en.wikipedia.org/wiki/Atenolol - cite_
note-BBB-1). Common adverse effects of atenolol include 
bradycardia, hypotension, fatigue, dizziness, depression, 
memory loss and impotence. At high doses, it is less cardio 
selective and may cause bronchospasm. As with all beta-
blockers, sudden withdrawal of atenolol can trigger rebound 
hypertension[1-4].
2. Case reports
2.1. Case 1 
   A 55 year old non-smoker and absolutely non-alcoholic 
male patient, diagnosed with both systolic and diastolic 
hypertension for last 1.5 years, was on titrated dose of oral 
amlodipine 10 mg once daily with excellent regulation 
of blood pressure. He presented with a gradual onset of 
swelling of extremities and abdominal distension after 
taking amlodipine for initial 1.5 months. S-amlodipine 
being considered as an alternative ‘switch over drug’ in 
patients developing pedal edema with amlodipine, he was 
started with oral S-amlodipine 10 mg once daily. However, 
the swelling was not reduced, and as a result, the patient 
was switched on to oral atenolol 50 mg once daily, after 
which the swelling subsided completely within the next 
2 weeks. His routine examination results, renal function, 
liver function, and cardiac status were essentially normal 
at that time. Since then, he was continuing atenolol with 
well control of hypertension. However, after 8 months of 
continuing atenolol, he presented with a 7 days history of 
gradually progressing nausea, vomiting, malaise, anorexia, 
fatigue, upper abdominal discomfort and jaundice. 
   On physical examination, his vital signs were within 
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normal limits. The skin was yellowish with scleral icterus, 
but without ecchymoses or petechiae. Cardiovascular and 
pulmonary findings were unremarkable. The abdomen 
was soft, but diffusely tender, particularly in right 
hypochondrium. There was no palpable organomegaly, 
rebound tenderness, guarding, or rigidity. Initial laboratory 
work-up findings are enumerated in Table 1. 
2.2. Case 2
   A 52 year old non-smoker and absolutely non-alcoholic 
female with a prior medical history of hypothyroidism 
and type 2 diabetes mellitus presented to the emergency 
department with 1 week history of crampy, mid-epigastric 
abdominal pain, non-bloody diarrhea and gradually 
developing jaundice. She had fever, nausea and vomiting, 
anorexia and profound fatigue for last 1 week. She did 
not have any pruritus, arthralgias, black tarry stools or 
dark urine. Drug history revealed, 3 weeks prior to this 
presentation, she was diagnosed with moderate systolic 
plus diastolic hypertension for which she was advised oral 
atenolol 100 mg tab once daily. Apart from that, she was 
taking 100 µg oral levothyroxine for last 10 years, 1g oral 
metformin for last 7 years and 500 mg oral calcium once 
daily for last 5 years. 
   On examination, she was afebrile and had stable vital 
signs. There was mild mid epigastric tenderness and no 
palpable organomegaly. Icterus was marked. Her initial 
laboratory investigation reports are elaborated in Table 1.
   Serological screening for viral hepatitis (hepatitis A, B, C, E 
and G virus, cytomegalovirus, herpes simplex, and Epstein-
Barr virus) were negative and HBV-DNA and HCV-RNA 
were not detected in either patient. Search for autoimmune 
liver disorders (anti nuclear antibodies, anti smooth muscle 
antibodies, and anti mitochondrial antibodies) were also 
negative. Results of iron, copper, ceruloplasmin metabolism 
and α1-antitrypsin concentrations were normal. Imaging 
studies (ultrasonography of whole abdomen and computed 
tomography of whole abdomen) in both these patients 
revealed normal hepatic echo texture, normal gall bladder 
and biliary structures with absence of any focal lesions or 
other diffused conditions in the liver. Upper GI endoscopy, 
12 lead electrocardiography and echocardiography were also 
well within normal limits.
   The 1st patient was non diabetic, non hyperlipidemic with 
no other significant medical or surgical disorders. However, 
the 2nd patient had co-existing hypothyroidism and type 2 
diabetes mellitus.
   There was no history of any herbal or any ‘over the 
counter’ drug intake in either patient. The 1st patient was 
previously on S-amlodipine 1.5 years back, before initiating 
atenolol. He was not taking any other drugs since then. But 
the 2nd patient was on 4 concomitant medications:
1. 100 mg atenolol once daily for last 3 weeks,
2. 100 毺g oral levothyroxine once daily for last 10 years, 
3. 1 g oral metformin once daily for last 7 years,
4. 500 mg oral calcium once daily for last 5 years.
   The 2nd patient was treated with oral metformin, 
levothyroxine and calcium supplements for considerable 
periods of time and her liver function test was well within 
normal limits, as demonstrated by the periodic monitoring 
Table 1
Relevant investigation results during the episodes of hepatotoxicities in 2 patients.
Serial 
Nos.
Parameters detected Detected values in patient 1 Detected values in patient 2 Normal range
1 Hemoglobin 14.7 g/dL 13.9  g/dL 13.3-16.2 g/dL
2 Total WBC count 10 500/毺L 9 700/毺L 4 000-11 000/毺L
3 ESR 25 mm after 1st h 23 mm after 1st h 0-15 mm/h
4 Platelet count 220×109/L 280×109/L 165-415×109/L
5 Fasting blood glucose 101 mg/dL 90 mg/dL 75-110 mg/dL
6 2 hours postprandial blood glucose 126 mg/dL 115 mg/dL 70-120 mg/dL
7 Serum urea 12.3 mg/dL 10.9 mg/dL 7-20 mg/dL
8 Serum creatinine 0.8 ng/mL 0.9 ng/mL 0.6-1.2 ng/mL
9 Serum sodium 136 meq/L 141 meq/L 136-146 meq/L
10 Serum potassium 4.1 meq/L 4.5 meq/L 3.5-5.0 meq/L
11 Serum amylase 55 U/L 61 U/L 20-96 U/L
12 Serum lipase 26 U/L 31 U/L 3-43 U/L
13 Serum lactate dehydrogenase 189 U/L 201 U/L 115-221 U/L
14
Liver 
function 
tests
Total bilirubin 5.4 mg/dL 4.8 mg/dL 0.3-1.3 mg/dL
Direct bilirubin 4.3 mg/dL 3.8 mg/dL 0.1-0.4 mg/dL
Indirect bilirubin 1.1 mg/dL 1.0 mg/dL 0.2-0.9 mg/dL
Serum glutamic oxaloacetic transaminase (SGOT) 555 U/L 453 U/L 12-38 U/L
Serum glutamic pyruvic transaminase (SGPT) 460 U/L 358 U/L 7-41 U/L
Alkaline phosphatase 176 U/L 157 U/L 33-96 U/L
Albumin 4.8 g/dL 4.1 g/dL 4.0-5.0 g/dL
Globulin 3.2 g/dL 3.5 g/dL 2.3-3.5 g/dL
Prothrombin time 19.9 s 17.7 s 12.7-15.4 s
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since the inception of above therapy, hence it is unlikely 
that these medications induced acute hepatocellular damage 
after more than 5 years of continuous use.
   The above 2 clinical cases, as supported by relevant 
blood biochemical reports and other investigations highly 
suggested those to be cases of hepatocellular jaundices, 
related to atenolol therapy. So, in both the patients, 
suspected atenolol was discontinued immediately. No other 
therapeutic modifications were done.  Both the patients were 
improved symptomatically within the next 2 weeks. Within 4 
weeks liver function tests were found to be nearly normal in 
both the patients (Table 2).
   The discontinuation of atenolol was resulted in complete 
symptomatic resolution along with normalization of elevated 
hepatic transaminases. None of the patients were re-
challenged with atenolol. Both the patients are now being 
treated with oral telmisartan 20 mg daily for hypertension 
with excellent regulation of their blood pressure.
3. Discussion
   Physical signs and symptoms evidenced by a remarkably 
high value of  hepatocellular  enzymes indicated 
hepatotoxicities in these 2 patients. Atenolol has been 
linked to rare cases of drug-induced liver injury. Hence, 
it is pertinent to evaluate other potential etiologies of 
hepatotoxicities in these patients. Drug interactions are 
very complex, but should always be kept in mind when 
confronted with adverse effects like hepatotoxicity. 
   In the 1st patient there was no possibility of drug 
interaction with the amlodipine metabolites and atenolol as 
the onset of hepatocellular damage i.e. sign and symptoms 
appeared after long duration of amlodipine withdrawn. 
Further, fixed dose combination of atenolol and amlodipine 
is widely accepted for their protective regulation of blood 
pressure to decrease the incidence of cardiovascular 
morbidity and mortality. 
   In the 2nd patient, either drug interaction among the 4 
concomitantly used drugs might have caused hepatocellular 
damage or a particular drug might be responsible for it. 
However, there have been no known interactions with any 
of the concomitant drugs taken by patient 2 in the literature, 
except few cases of metformin induced hepatotoxicities[5-8]. 
Rather this widely prescribed polypharmacy strategy often 
resulted into safe and sustainable therapeutic outcome of 
these co morbid conditions.
   Atenolol has been associated with a minimally increased 
rate of serum amino transferase elevations and have very 
rarely been associated with clinically apparent liver 
injury[9]. Isolated case reports of idiosyncratic hepatotoxicity 
due to atenolol have been published, but there have 
been no reported case series[10]. In this report, features 
of hepatotoxicity were evident after 8 months in patient 
1 (chronic) and within 3 weeks in patient 2 (acute) of oral 
atenolol therapy and symptoms of hepatotoxicities were 
resolved on discontinuation of the drug and different 
investigation reports verified reversal of the processes in 
both the cases. In order to evaluate the relationship between 
the liver manifestation and atenolol treatment, the Council 
for International Organizations of Medical Sciences/Roussel 
Uclaf Causality Assessment Method (CIOMS/RUCAM) scale 
has been used[11]. The CIOMS/RUCAM scale indicated 
a ‘probable’ relationship between atenolol therapy and 
hepatotoxicities. Extensive literature survey has suggested 
a favorable impact of atenolol on hepatic function. However 
3 reports of acute hepatitis have been documented with 
atenolol.  There are also some reports of hepatotoxicities 
with other beta blockers like labetolol, betaxolol, esmolol, 
etc[12-15].
   A 73-year-old man with hypertension developed pruritus 
and right upper quadrant abdominal pain associated with 
elevated serum liver function tests within 9 months after 
switching from methyldopa to atenolol. Liver biopsy revealed 
canalicular and centrolobular cholestasis. No other etiology 
was found. The patient’s signs and symptoms of hepatitis 
resolved within 1-4 weeks after stopping atenolol. Re-
challenge was not done[16].
Table 2
Relevant blood investigation results after hepatotoxicities were resolved in 2 patients (responses to de challenge).
Serial 
Nos.
Parameters detected Detected values in Patient 1 Detected values in Patient 2 Normal range
1 Hemoglobin 14.5 g/dL 13.8  g/dL 13.3-16.2 g/dL
2 Total WBC count 9 500/毺L 9 200/毺L 4 000-11 000/毺L
3 ESR 15 mm after 1st h 13 mm after 1st h 0-15 mm/h
4 Platelet count 225×109/L 278×109/L 165-415×109/L
5
Liver 
function 
tests
Total bilirubin 1.8 mg/dL 1.2 mg/dL 0.3-1.3 mg/dL
Direct bilirubin 1.0 mg/dL 0.8 mg/dL 0.1-0.4 mg/dL
Indirect bilirubin 0.8 mg/dL 0.4 mg/dL 0.2-0.9 mg/dL
Serum glutamic oxaloacetic transaminase (SGOT) 67 U/L 61 U/L 12-38 U/L
Serum glutamic pyruvic transaminase (SGPT) 56 U/L 62 U/L 7-41 U/L
Alkaline phosphatase 107 U/L 97 U/L 33-96 U/L
Albumin 4.9 g/dL 4.0 g/dL 4.0-5.0 g/dL
Globulin 3.2 g/dL 3.4 g/dL 2.3-3.5 g/dL
Prothrombin time 14.8 s 13.9 s 12.7-15.4 s
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   In another case, a 78-yr-old man developed hepatic 
dysfunction within few days of starting atenolol. Blood 
tests revealed abnormal liver function with markedly 
raised liver enzymes and moderately raised bilirubin and 
alkaline phosphatase, suggesting hepatocellular damage 
and some cholestasis. Atenolol was stopped on admission 
and subsequently there was an improvement in liver 
function and was almost normal after 2 weeks. Due to this 
improvement and absence of other causes, it was suspected 
that liver dysfunction was atenolol-induced[17].
   Also, in another case report, a 57-year-old liver 
transplanted woman with the known history atenolol therapy 
for hypertension for 3 years prior to liver transplantation 
was reintroduced atenolol at a dose of 100 mg/day because 
of recurrence of hypertension. After 1 month, she presented 
with acute hepatitis which was evidenced by portal and 
centrilobular inflammatory lesions. An initial diagnosis 
considered in this patient was acute rejection. This 
diagnosis had to be reconsidered because of the unfavorable 
outcome, despite specific treatment of rejection. Moreover, 
the patient had been treated with atenolol for 3 years before 
liver transplantation; in the absence of any other etiology, 
the possibility that she had atenolol-induced cirrhosis may 
therefore be considered and favorable outcome was achieved 
only upon atenolol withdrawl[18].
   The exact insight of mechanism of how atenolol related 
hepatotoxicity is debatable as then agent has a little or 
no hepatic metabolism, but their prevalence must be 
correlated as hepatotoxicity is a serious medical condition 
and can result in grave prognosis. One published case 
reports hypothesized an immune-mediated mechanism 
of hepatotoxicity based on the inflammatory infiltrates 
observed in the liver biopsy specimens[19,20].
   When prescribing atenolol, a commitment to baseline 
screening and monitoring liver functions may be required to 
mitigate the likelihood of developing hepatic abnormalities 
and their associated deleterious consequences. Physicians 
must have a high degree of suspicion and should remain 
cautious and warn patients to report any symptoms of 
hepatotoxicity after taking this drug. There should be 
provisions for early withdrawing the offending drug and 
supportive therapy to lower the intensity of this unexpected 
potential life threatening drug induced complication.
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